Bioventus (BVS) Stock Forecast & Price Target

Bioventus is expected to continue driving revenue growth in 2026 through its well-established business areas such as pain treatments and surgical solutions, with potential for accelerated growth in the high-single digits range. Management is also investing in key growth areas, such as peripheral nerve stimulation and platelet-rich plasma, to drive future growth. The company's strong financials, including a solid cash flow from operations and expected double-digit profitability, make it a promising investment opportunity for investors. Furthermore, Bioventus' current valuation presents a potential discount to its inherent value, signaling a strong potential for future market growth.

Bioventus is a medical device company operating in two segments with three main business areas; it expects 200-bps of top-line growth in 2026 driven by PNS and PRP initiatives, however, its HA knee injection business accounts for 98%-99% of the pain treatments segment's revenue. Despite having a presence in multiple geographic regions, its U.S. segment generates 88% of its total revenue, indicating international growth opportunities may be limited.